Syndicate content

Archive - Jul 20, 2017


AAAAI Lifetime Achievement Award Will Go to Yale Physician/Scientist, Immunology Giant, & Exosome Pioneer: Philip Askenase

BioQuick News has recently learned that Philiip Askenase, MD, will be honored with a life-time achievement award--Distinguished Scientist Awardee of the AAAAI for 2018—by the American Academy of Allergy, Asthma, and Immunology. This award is presented annually to recognize scientific contributions of a single individual to the field of Allergy and Immunology that have advanced allergy and immunology research, and for leadership contributions to the specialty. Generally, only one such award is given each year. Dr. Askenase, Professor of Medicine (Immunology) at the Yale School of Medicine is the first from Yale ever selected for this prestigious award. The award will be given before a large audience in Orlando, Florida at the Annual AAAAI meeting in early March 2018. The AAAAI has a total of about 7,000 members from all over the world. Dr. Askenase will present a lecture at the time of the award presentation and the provisional title for his address is “The Role of Exosome Delivery of miRNAs in Allergy, Asthma and Immunology.” Working with the well-known models of cutaneous immune hypersensitivity and immunity, Dr. Askenase discovered the series of steps from challenge with antigen, in a sensitized host, to the entry of T cells into the site of challenge. This work uncovered previously unrecognized roles of: B-1a B cells, NKT cells, IL-4, complement, serotonin, and mast cells. These findings are relevant to the diagnosis and therapy of allergic and autoimmune diseases, as well as cancers and transplantation. Current work in the Askenase lab centers on the very exciting newly discovered exosomes that are nanoparticles released by all cells sending RNA functional messages to each other.

Study Demonstrates Use of ACE Technology for Direct Isolation of Exosomes

On July 12, 2017, Biological Dynamics announced the publication of data in ACS Nano demonstrating that the company's proprietary lab-on-a-chip ExoVerita™ system can simplify and streamline the process for isolation and recovery of exosomes. The company is using this technology to develop a portfolio of minimally-invasive diagnostic tests to provide faster answers to critical clinical questions in high-burden diseases, such as cancer, traumatic brain injury, and infectious diseases. The ACS Nano article, published online on July 3, 2017, is titled “Rapid Isolation and Detection of Exosomes and Associated Biomarkers from Plasma.” Exosomes are cell-derived, extracellular vesicles that enable communication between cells. They are secreted from most cell types and released in bodily fluids such as urine, blood plasma, and saliva. Due to their stability and ability to transport information about their origin and the state of their parental cells, exosomes are believed to have great potential to power the next generation of liquid biopsies and cancer biomarkers. "Current exosome isolation methods are generally expensive, complex, and cumbersome, which could limit large-scale diagnostic applications," said Michael Heller, PhD, principal investigator on the paper and scientific advisory board member of Biological Dynamics. "This study describes a relatively simple, rapid, and non-destructive method for the isolation of exosomes, that preserves their valuable biomarker information for direct analysis.